“Previously it was called lung or breast cancer, but today it is known that there are different kinds of lung cancer, for example. The name is the same, but the last name changes depending on the genetic characteristics of the tumor and we we need to determine which are the mutations in each tumor to know if the patient is a candidate or not for a specific drug for that tumor”, he declares.
The company, which has laboratories in Argentina, Mexico and Brazil, has the capacity to collect blood and tissue samples from patients in various cities in Latin America, which opens the opportunity for sequences of patients in the region to be carried out , and with it, clinical studies that consider them, since Nicolás Kirchuk declares that now they are carried out only with European or American patients, therefore, medicines would be developing with genetic data from Latin Americans.
The biomarkers market had a global value of 51.18 billion dollars in 2020 and will reach 147.59 billion by 2028, with an annual growth rate of 14.2% in the period, according to an analysis by Grand View Research.
“We are here to take a large percentage of that market, because we are not only having an impact on the genetic diagnosis of patients in Latin America, but we are also having an impact on the development of new drugs by providing the genetic data of our patients”, comments the manager .
Getting to Central America from Mexico
The company started operations in 2014, and extended its genetic sequencing laboratories to Mexico and Brazil, from where they plan to grow from 10 to 17 the countries in which they collect genetic markers. The plan is, from Mexico, care for patients located in Central America.